Abstract
Mycobacterium avium is a human pathogen that causes infection in immunocompetent as well as immunocompromised patients. Infection is acquired both by the respiratory and gastrointestinal routes, and bacterial invasion of mucosal epithelial cells is characteristic. M. avium crosses the mucosal barrier without triggering substantial inflammatory response. Once in the intestinal submucosa or in the alveolar space M. avium infects macrophages. Intracellular bacteria block the production of cytokines involved in the host response against the infection, such as TNF-α and IL-12, and suppress antigen presentation by the macrophage. Innate response against the infection is effective to certain extent but the ability of the bacterium to remain “silent” for a period of time prevents neutrophil and NK cells from effectively controlling the establishing of the infection. CD4+ T cells as well as CD8+ T cells are activated, although only CD4+ T cells appear to be effective in inducing anti-M. avium activity in macrophages. M. avium-specific CD8+ T cells undergo apoptosis early in the infection. Therefore, the immune mechanisms of the host and bacterial strategies for survival are complex and fascinating.
Keywords: Cytokines, macrophages, immunocompetent
Current Pharmaceutical Design
Title: Role of Type I Cytokines in Host Defense Against Mycobacterium avium Infection
Volume: 9 Issue: 1
Author(s): Lia Danelishvilli and Luiz E. Bermudez
Affiliation:
Keywords: Cytokines, macrophages, immunocompetent
Abstract: Mycobacterium avium is a human pathogen that causes infection in immunocompetent as well as immunocompromised patients. Infection is acquired both by the respiratory and gastrointestinal routes, and bacterial invasion of mucosal epithelial cells is characteristic. M. avium crosses the mucosal barrier without triggering substantial inflammatory response. Once in the intestinal submucosa or in the alveolar space M. avium infects macrophages. Intracellular bacteria block the production of cytokines involved in the host response against the infection, such as TNF-α and IL-12, and suppress antigen presentation by the macrophage. Innate response against the infection is effective to certain extent but the ability of the bacterium to remain “silent” for a period of time prevents neutrophil and NK cells from effectively controlling the establishing of the infection. CD4+ T cells as well as CD8+ T cells are activated, although only CD4+ T cells appear to be effective in inducing anti-M. avium activity in macrophages. M. avium-specific CD8+ T cells undergo apoptosis early in the infection. Therefore, the immune mechanisms of the host and bacterial strategies for survival are complex and fascinating.
Export Options
About this article
Cite this article as:
Danelishvilli Lia and Bermudez E. Luiz, Role of Type I Cytokines in Host Defense Against Mycobacterium avium Infection, Current Pharmaceutical Design 2003; 9 (1) . https://dx.doi.org/10.2174/1381612033392369
DOI https://dx.doi.org/10.2174/1381612033392369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plasma Cytokine Levels in Overweight Versus Obese Disease-Free Perimenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Costimulation, Coinhibition and Cancer
Current Cancer Drug Targets The IL-17 Family of Cytokines - Applications in Respiratory Medicine and Allergology
Recent Patents on Inflammation & Allergy Drug Discovery Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals
Current Drug Safety Metaxalone Suppresses Production of Inflammatory Cytokines Associated with Painful Conditions in Mouse Macrophages RAW264.7 Cells <i>in Vitro</i>: Synergistic Effect with β-caryophyllene
Current Molecular Medicine Antiinflammatory Effects of H1-Antihistamines: Clinical and Immunological Relevance
Current Pharmaceutical Design Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Current Cancer Drug Targets Inflammatory Signaling Networks as Targets for Pharmacological Intervention of Chronic Diseases
Current Signal Transduction Therapy Clinical Grade Stem Cell Culture
Recent Patents on Regenerative Medicine Nucleoside Transporter Proteins
Current Vascular Pharmacology Recurrent Hepatitis C After Liver Transplantation
Anti-Infective Agents Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets Advances in Nano Drugs for Cancer Chemotherapy
Current Cancer Drug Targets Cytokines, Inflammation and Colon Cancer
Current Cancer Drug Targets Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Biomedical Applications of Protein Microarrays
Current Medicinal Chemistry Chitin and β-Glucan Polysaccharides as Immunomodulators of Airway Inflammation and Atopic Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews Acute Graft-Versus-Host Disease-Challenge for a Broader Application of Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy